1.89
X 4 Pharmaceuticals Inc stock is traded at $1.89, with a volume of 380.09K.
It is down -4.55% in the last 24 hours and down -52.27% over the past month.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
See More
Previous Close:
$1.98
Open:
$2
24h Volume:
380.09K
Relative Volume:
2.05
Market Cap:
$20.61M
Revenue:
-
Net Income/Loss:
$-16.76M
P/E Ratio:
-23.62
EPS:
-0.08
Net Cash Flow:
$-132.97M
1W Performance:
-5.50%
1M Performance:
-52.27%
6M Performance:
-91.51%
1Y Performance:
-88.84%
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals Inc
Sector
Industry
Phone
857-529-8300
Address
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
XFOR
X 4 Pharmaceuticals Inc
|
1.89 | 20.61M | 0 | -16.76M | -132.97M | -0.08 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-12-23 | Downgrade | B. Riley Securities | Buy → Neutral |
Aug-30-23 | Resumed | B. Riley Securities | Buy |
Dec-22-22 | Initiated | Cantor Fitzgerald | Overweight |
Dec-12-22 | Initiated | Piper Sandler | Overweight |
Dec-23-19 | Initiated | Oppenheimer | Outperform |
Dec-18-19 | Initiated | ROTH Capital | Buy |
Dec-09-19 | Upgrade | Citigroup | Neutral → Buy |
Dec-05-19 | Initiated | B. Riley FBR | Buy |
Jun-07-19 | Initiated | Stifel | Buy |
Jun-05-19 | Initiated | Cowen | Outperform |
View All
X 4 Pharmaceuticals Inc Stock (XFOR) Latest News
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Short Interest Up 27.1% in May - Defense World
X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association - MarketScreener
Unicycive Sets 1-for-10 Reverse Split: What This Means for 126M Outstanding Shares - Stock Titan
XFOR Presents Positive Phase 2 Trial Results for Mavorixafor at EHA Congress | XFOR Stock News - GuruFocus
X4 Pharmaceuticals presents positive data from neutropenia trial By Investing.com - Investing.com Canada
X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA) - marketscreener.com
Layoff Tracker: ADC Therapeutics Cutting 30% of Staff, Closing London Research Facility - BioSpace
Fierce Biotech Layoff Tracker 2025: ADC Tx lets go of 30% of workers; Vertex sheds 125 staffers - Fierce Biotech
Brokers Offer Predictions for XFOR FY2026 Earnings - Defense World
X4 Pharmaceuticals Elects New Director at Annual Meeting - TipRanks
X4 Pharmaceuticals Grants Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA - marketscreener.com
X4 Pharmaceuticals Granted Fast Track Designation For Mavorixafor For Treatment Of Chronic Neutropenia By US FDA - MarketScreener
X4 Pharmaceuticals gains on fast-track designation for mavorixafor for treatment of chronic neutropenia - MSN
X4 Pharmaceuticals (XFOR) Gains FDA Fast Track Status for Mavorixafor | XFOR Stock News - GuruFocus
FDA grants fast track status to X4’s neutropenia drug - Investing.com
X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA - MarketScreener
Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S - Quantisnow
Stock split by pharma company: Record date this week; Rs 297 crore order windetails - ET Now
Director Dugan Richard W was granted 59,225 shares, increasing direct ownership by 50% to 177,454 units (SEC Form 4) - Quantisnow
Director Honore Tage was granted 59,225 shares, increasing direct ownership by 92% to 123,469 units (SEC Form 4) - Quantisnow
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
SEC Form S-8 filed by Vanda Pharmaceuticals Inc. - Quantisnow
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Why Skyrocketed Recursion Pharmaceuticals, Inc. (RXRX) Today - Insider Monkey
60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format - The Manila Times
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | XFOR Stock News - GuruFocus
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Investors Still Aren't Entirely Convinced By Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) Revenues Despite 54% Price Jump - simplywall.st
Bankrupt 23andMe to be bought by pharmaceutical company Regeneron for $256 million - AOL.com
Top 10 pharma companies in India by market cap [2025] - Forbes India
Director Moos Walter H was granted 2,500 shares, increasing direct ownership by 24% to 12,722 units (SEC Form 4) - Quantisnow
Director Hannah Alison L. was granted 2,500 shares, increasing direct ownership by 31% to 10,625 units (SEC Form 4) - Quantisnow
ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing - GlobeNewswire
Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028 - Benzinga
Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee - Yahoo Finance
X4 Pharmaceuticals (NASDAQ:XFOR) Shares Down 4% – Here’s Why - Defense World
SEC Form DEFA14A filed by Vanda Pharmaceuticals Inc. - Quantisnow
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Twinbeech Capital LP - MarketBeat
ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares - Yahoo Finance
President and CEO Polymeropoulos Mihael Hristos bought $43,995 worth of shares (10,000 units at $4.40), increasing direct ownership by 0.43% to 2,325,731 units (SEC Form 4) - Quantisnow
President and CEO Polymeropoulos Mihael Hristos bought $84,472 worth of shares (20,000 units at $4.22), increasing direct ownership by 0.87% to 2,315,731 units (SEC Form 4) - Quantisnow
23andMe to Be Bought by Regeneron Pharmaceuticals, a Biotech Company, for $256 Million - The New York Times
Bankrupt 23andMe Expected to Be Purchased for $256M - People.com
Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025 - Quantisnow
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Waters Corp's India business boosted by rush for weight-loss drugs - Reuters
X4 Pharmaceuticals Announces Upcoming Presentation Of Phase 2 Chronic Neutropenia Trial Data At The 30Th Annual Eha Congress - marketscreener.com
X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress - marketscreener.com
X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data At the 30Th Annual Eha Congress - marketscreener.com
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
X 4 Pharmaceuticals Inc Stock (XFOR) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Baldry Mark | Chief Commercial Officer |
Nov 15 '24 |
Buy |
0.34 |
13,404 |
4,598 |
129,173 |
Ragan Paula | President and CEO |
Jan 24 '25 |
Sale |
0.45 |
76,473 |
34,719 |
1,087,386 |
Mostafa Adam S. | Chief Financial Officer |
Jan 24 '25 |
Sale |
0.45 |
74,773 |
33,947 |
0 |
Baldry Mark | Chief Commercial Officer |
Jan 24 '25 |
Sale |
0.45 |
29,159 |
13,241 |
94,123 |
DiBiase Mary | Chief Operating Officer |
Jan 24 '25 |
Sale |
0.45 |
22,258 |
10,094 |
490,980 |
Arbet-Engels Christophe | Chief Medical Officer |
Jan 24 '25 |
Sale |
0.45 |
11,624 |
5,284 |
14,207 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):